Table 3.
Comorbidities as reported by the patients with PRP, by the Level of Diagnostic Certainty
| Comorbidity | Level 1 n=50 |
Level 2 n=15 |
Level 3 n=30 |
Level 4 n=5 |
TOTAL n=100 |
|---|---|---|---|---|---|
| Cutaneousa | 7 (14%) | 2 (13%) | 7 (23%) | 1 (20%) | 17 (17%) |
| Myasthenia Gravis | 0 (0%) | 1 (7%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Celiac Sprue | 1 (2%) | 1 (7%) | 0 (0%) | 0 (0%) | 2 (2%) |
| Myositis | 1 (2%) | 1 (7%) | 0 (0%) | 0 (0%) | 2 (2%) |
| Hypothyroidism | 10 (20%) | 2 (13%) | 2 (7%) | 0 (0%) | 14 (14%) |
| Malignancy | 5 (10%) | 2 (13%) | 1 (3%) | 1 (20%) | 9 (9%) |
| HIV | 0 (0%) | 1 (7%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Dyslipidemia | 9 (18%) | 5 (33%) | 5 (17%) | 1 (20%) | 20 (20%) |
| Diabetes Mellitus | 4 (8%) | 1 (7%) | 0 (0%) | 1 (20%) | 6 (6%) |
| Cardiovascular Disease (HTN, CAD, HF, etc.)b | 1 (2%) | 5 (33%) | 1 (3%) | 0 (0%) | 7 (7%) |
| Other | 6c (12%) | 5d (33%) | 2e (7%) | 0 (0%) | 13 (13%) |
| No comorbidities | 19 (38%) | 6 (40%) | 13 (43%) | 2 (40%) | 40 (40%) |
a
Cutaneous conditions other than PRP
b
HTN, Hypertension; CAD, Coronary Artery Disease; HF, Heart Failure
c
Normal pressure hydrocephalus, sleep apnea, colon polyps, inflammatory bowel disease, spinal stenosis, thrombocytopenia, rheumatoid arthritis
d
Cardiac conduction deficits, alopecia
e
Peptic ulcer disease, sleep apnea, degenerative joint disease